RHHBF News and Press, Roche Holding Ltd From 04/24/24

2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...

2024-04-18 13:15:50 ET More on TG Therapeutics TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG Therapeutics: Briumvi Growth Story Appears Intact TG Therapeutics jumps after second consecutive quarter...

2024-04-17 13:26:56 ET Summary Tempest Therapeutics, Inc. achieved positive results from phase 1b/2 study using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC; Significant improvements in both confirmed and unconfirmed responses. Updated results fr...

2024-04-17 10:24:12 ET Summary TG Therapeutics shares are down 60% from their 52-week high after rival MS therapy Ocrevus achieved non-inferiority as a subcutaneously injected therapy. Initial sales of TG Therapeutics' anti-CD20 MS treatment Briumvi were solid, generating $92 mill...

2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

2024-04-12 08:53:13 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune: Drug Approval Now Imminent? FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4 Seeking Alpha’s Quant Rating...

2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...

2024-04-09 11:00:51 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript Syros Pharmaceuticals: Rising Despite Dilution, A Must Look Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $...

2024-04-04 13:11:10 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation Seeking A...